The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1718
December 23, 2024
View Complete Issue         Table of Contents 2019 
Elafibranor (Iqirvo) for Primary Biliary Cholangitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Elafibranor (Iqirvo) for Primary Biliary Cholangitis
December 23, 2024 (Issue: 1718)
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated receptor (PPAR) agonist, has been granted accelerated approval by the FDA for treatment of primary biliary cholangitis (PBC) in adults. It is indicated for use in combination...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Elafibranor (Iqirvo) for Primary Biliary Cholangitis
Article code: 1718b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.